ArticleFrontiers in oncology2026
Access to molecular diagnostics for CNS tumors through international outsourcing: experience from Jordan.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Molecular profiling is now integral to the diagnosis, risk stratification, and treatment of central nervous system (CNS) tumors following the 2021 WHO Classification (WHO CNS5). However, access to molecular diagnostics remains severely limited in settings with limited resources. International outsourcing to accredited reference laboratories represents a potential bridging strategy, yet systematic data on its feasibility and clinical impact in the LMICs are lacking. Methods: We conducted a retrospective review of CNS tumor cases at King Hussein Cancer Center (KHCC), Amman, Jordan, that underwent outsourced molecular testing at the Hospital for Sick Children in Toronto, Canada, between 2021 and 2023. Four test types were ordered: medulloblastoma subgrouping by NanoString nCounter-based gene expression profiling, TruSight pan-cancer RNA sequencing, low-grade fusion gene analysis, and C19MC fluorescence Results: A total of 105 patients underwent outsourced molecular tumor testing (87% pediatric; median age 10 years; 54% male). Tumor types included medulloblastoma (52%), low-grade glioma (LGG, 30%), high-grade glioma (HGG, 12%), and others (6%). Of the 119 samples that reached the reference laboratory, 109 (92%) yielded a conclusive molecular result, with the highest rate in medulloblastoma (94%) and the lowest in ependymoma (33%). The median overall TAT was 26 days (range 13-140 days), and the total expenditure was 153,506 US Dollars. Molecular testing led to a change in diagnosis in 4 cases (4%): 3 major changes (reclassification of BCOR sarcoma to solitary fibrous tumor, ependymoma to pilocytic astrocytoma, and pediatric-type diffuse low-grade glioma with Conclusion: International outsourcing of molecular diagnostics is a feasible and clinically impactful strategy for CNS tumor management at limited-resource settings, enabling WHO CNS5-integrated diagnoses and access to precision therapy. The TAT and cost per tumor sample are relatively acceptable given the benefits of a more accurate diagnosis and the possibility of finding a targetable alteration. Permanent solutions would require investment in regional molecular diagnostic infrastructure through in-house capacity building, laboratory networks, and international twinning programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.